Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
With
National Institutes of Health (NIH)
National Cancer Institute (NCI)
PRIMARY OBJECTIVES:
I. To assess the ability of Cu-64-TP3805 (copper Cu 64 TP3805) to detect prostate cancer (PC), or absence thereof, within the prostate gland.
Age
21–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Ability to provide signed informed consent and willingness to comply with protocol requirements
Persistently elevated PSA
Scheduled for magnetic resonance imaging (MRI) fusion/transrectal ultrasound (TRUS) biopsy, followed by histology
Agree to use an acceptable form of birth control for a period of 7 days after the Cu-64-TP3805 injection
You may not be if
Participating would significantly delay the scheduled standard of care therapy
Administered a radioisotope within 10 physical half-lives prior to study drug injection
Have any medical condition or other circumstances that, in the opinion of the investigator, would significantly decrease obtaining reliable data, achieving study objectives or completing the study
Clareo Health | Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA
